Piper Jaffray analyst JP Kim raised his price target on Tandem Diabetes to $78 and kept his Overweight rating after its Q1 results “far exceeded” expectations, saying the company is “clearly” capturing market share in in the pump market. The analyst also cites the momentum of Tandem Diabetes based on the management’s indication that only about a quarter of the company’s sales were in January, anticipating no change in the positive “competitive dynamic” of its market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.